CARMAT Announces the First Commercial Implants of Its Aeson ® Artificial Heart Outside the European Union

CARMAT (ALCAR) announced the first commercial implants of its Aeson artificial heart outside the EU, with two procedures performed in Israel during the week of May 26, 2025. These implants, conducted at Hadassah Ein Kerem Hospital and Sheba Medical Center, expand the commercial use of Aeson to five countries and reflect growing confidence in the device. CARMAT, a French MedTech company, aims to position Aeson as an alternative to heart transplants for patients with advanced biventricular heart failure, though the company's cash runway is limited to mid-June 2025.

Analysis

CARMAT (ALCAR) has achieved a significant operational milestone with the first commercial implants of its Aeson® artificial heart outside the European Union, evidenced by two procedures successfully performed in Israel during the week of May 26, 2025. This expansion brings the total number of countries with commercial Aeson® implants to five, underscoring growing acceptance and trust in the device among healthcare professionals as a therapeutic alternative for advanced biventricular heart failure. While these developments at Hadassah Ein Kerem Hospital and Sheba Medical Center represent progress in CARMAT's ambition to position Aeson® as an alternative to heart transplants, a critical financial caveat is highlighted in the announcement: the company's current cash runway is limited to mid-June 2025, excluding a flexible equity financing line. This precarious financial position, reflected in the mixed sentiment score of -0.2, presents a substantial near-term risk that overshadows the positive clinical and commercial advancements. The company also faces ongoing challenges typical of MedTech firms, including the pace of sales development, clinical trial outcomes, and regulatory landscapes, particularly as it continues its Early Feasibility Study in the United States.

Key Decisions for Investors

• Investors should closely monitor CARMAT's announcements regarding its financing situation and any measures taken to extend its cash runway beyond the critical mid-June 2025 deadline.
• The successful commercial expansion into Israel is a positive indicator of Aeson®'s market potential, but this must be weighed against the immediate and significant financial solvency risk.
• Consider the high-risk, high-reward nature of CARMAT; while the technology is advancing, the short-term viability hinges on securing additional funding imminently.